Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diacerein + methotrexate
- Development stage
- Phase 2
- Lead developer
- TRB Chemedica
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
A combination therapy consisting of diacerein, a slow-onset anthraquinone IL-1 inhibitor, and methotrexate, a disease-modifying antirheumatic drug (DMARD). This combination is used primarily for patients with rheumatoid arthritis who have an inadequate response to methotrexate alone. Diacerein is metabolized to rhein, its active form, and has shown potential benefits in reducing pain, improving joint function, and decreasing disease activity when added to methotrexate therapy.
02
Targets
DHFR (Dihydrofolate reductase)HMGB1 (High mobility group protein B1)IL1A (Interleukin 1 alpha)
Beyond the preview
Go deeper on diacerein + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diacerein + methotrexate.